- AVXL reported positive topline data from their trial for Rett syndrome in adults on Feb 1, 2022.
- However, the results were met with much skepticism or cynicism, due to changes to the trial's endpoints, registered on the clinicaltrials.gov site that was submitted on Jan 18.
- AVXL CEO said the changes were made in Dec 2021, when the patients were enrolled, but BEFORE the company had the data. The January 18 update was done by the CRO.
- I take a look at the results and share my thoughts here.
For further details see:
Anavex: The First Impression May Not Be The Right Impression